R01AG064877

Genetic Architecture of Alzheimer's Disease Proteinopathies - Project Summary/Abstract

In order to enhance and focus research on Alzheimer's Disease (AD)-specific proteinopathies, the 2018 research framework proposed by the National Institute on Aging and Alzheimer's Association (NIA-AA) recommends that AD be defined by its specific biological signatures that can be documented at autopsy or in living people by biomarkers, rather than by its non-specific neurodegenerative and clinical syndromic features.

Of the three proposed biomarkers by the NIA-AA research framework in living people (amyloid-beta (Aβ), pathologic tau, and neurodegeneration), only the two AD-specific proteinopathies (Aβ and pathologic tau) are considered obligatory for the biological definition of AD, while neurodegeneration, although contributing to cognitive impairment and being part of the fully manifested disease, can also occur in other brain disorders and thus is not specific to AD.

The purpose of this harmonized biological definition of AD in living people that includes the preclinical phase is to distinguish AD from other types of brain disorders and dementia, to accelerate and focus research on AD-specific proteinopathies that manifest decades before the clinical manifestation of first symptoms of AD, to enhance better understanding of the underlying mechanisms of AD clinical expression, and to use (and discover) targeted disease modifying interventions that can prevent or delay the onset of AD symptoms.

Our ongoing and long-term research interest coincides well with the NIA-AA research framework in living people where we have already performed genome-wide association studies (GWAS) on cerebrospinal fluid (CSF) Aβ42/tau levels and Aβ deposition in the brain measured by amyloid-PET and identified known and novel associations in the APOE and non-APOE regions. However, the identified signals do not explain all of the phenotypic variation in the two AD-specific proteinopathies or endophenotypes.

Here, we propose a collaborative study between leading experts in the field to extend our ongoing efforts to delineate the complete genetic basis of the two AD-specific proteinopathies (Aβ and pathologic tau) by whole genome sequencing (WGS) using well-characterized and large amyloid-PET and CSF Aβ42/tau datasets with clinical outcomes of dementia. We will then test the effects of identified significant variants on downstream neurodegeneration markers and perform extensive bioinformatics and functional studies.

The primary objective of this application is to perform and analyze WGS in adequately powered large discovery samples with well-characterized Aβ and tau data, along with clinical outcomes of dementia, to identify putative functional variants associated with Aβ and tau pathologies. These findings will then be replicated in independent and large samples with Aβ and tau data.

We will integrate genetic information to create polygenic risk scores in order to predict Aβ and tau pathologies. Additionally, we will examine the role of AD pathology-associated variants with downstream neurodegeneration, neuropathologies that coexist with AD, and the risk and age-at-onset of AD.

Finally, we will functionally characterize genetic associations using bioinformatics, causality tests, and in vitro experiments to understand their roles in affecting gene expression as expression quantitative traits loci, affecting intracellular and extracellular APP/Aβ and tau levels, and in myeloid cell function.

The successful completion of this study will help to identify novel AD-related genes and pathways, and to uncover underlying possible mechanisms for AD.

University Of Pittsburgh - Of The Commonwealth System Of Higher Education

NOT APPLICABLE

93.866 - Aging Research

National Institute on Aging (NIA) [HHS - NIH]

Pittsburgh, Pennsylvania 15213 United States

Single Zip Code

NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed) (PA-18-484)

Amendment Since initial award the total obligations have increased 274% from $2,243,331 to $8,382,548.